Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 40 peer-reviewed journal articles Updated
Hematology · Beta-thalassemia

How Much Do Zynteglo and Casgevy Gene Therapies Cost?

At a Glance

Zynteglo costs approximately $2.8 million and Casgevy is priced at around $2.2 million. To manage these high costs, insurers often use value-based agreements tied to treatment success. However, patients may still face significant out-of-pocket expenses for travel, lodging, and caregiver support.

In this answer

4 sections

01

Value-Based Agreements Explained

02

How Insurance and Medicaid Navigate Approvals

03

The Hidden Financial Reality for Patients

04

One-Time Cost vs. Lifetime Care

The list prices for these one-time gene therapies are in the multi-million dollar range: Zynteglo is priced at approximately $2.8 million, and Casgevy is listed at around $2.2 million per patient [1][2][3]. These high costs reflect the complex research and development process, the sophisticated manufacturing required to edit your own cells (autologous cells), and the manufacturers’ need to recoup investments from creating a single-use, transformative treatment [3][4][5].

While the initial price tag is staggering, paying for these therapies does not work like a traditional pharmacy prescription. Insurers, manufacturers, and treatment centers use complex financial structures and strict eligibility rules to navigate these massive costs.

Value-Based Agreements Explained

To address the uncertainty of long-term success and make these high prices financially sustainable for the healthcare system, manufacturers and payers frequently use value-based agreements, which are also known as outcomes-based pricing [6][7][8].

Under these agreements, payment is directly linked to how well the therapy works for the individual patient [7][2]. For beta-thalassemia gene therapies, financial arrangements are heavily tied to achieving transfusion independence [9][10][11]. Transfusion independence means the patient maintains a target hemoglobin level (usually ≥9 g/dL) without needing a red blood cell transfusion for at least 12 months [11][10].

If a patient receives the gene therapy but fails to reach or maintain this milestone, the manufacturer may offer a rebate or refund to the insurance company [9][6][7]. This ensures that payers and manufacturers share the financial risk if the therapy does not work as expected [7][12][13].

How Insurance and Medicaid Navigate Approvals

Medicaid and private insurers are increasingly turning to value-based contracts to manage the massive budget impact of a sudden multi-million dollar claim [7][14][15].

  • Medicaid Solutions: The Centers for Medicare & Medicaid Services (CMS) has introduced the Cell and Gene Therapy (CGT) Access Model [7]. This voluntary initiative is designed to help state Medicaid programs negotiate and participate in outcome-based pricing agreements [7]. Practically, this aims to make it easier for state Medicaid programs to approve your treatment without bankrupting state budgets [7][2].
  • Strict Patient Eligibility: Because of the high cost, insurers enforce rigorous clinical eligibility rules before granting a prior authorization. Getting approval usually requires precise genetic confirmation of your beta-thalassemia severity [16][10]. Insurers also frequently require proof that you do not have an HLA-matched sibling donor—a brother or sister whose tissue type matches yours closely enough to perform a traditional stem cell transplant safely [10][11][17].

The Hidden Financial Reality for Patients

While value-based agreements protect the insurance company’s bottom line, they do not automatically protect the patient from massive out-of-pocket expenses [18][19].

Receiving gene therapy requires a process called myeloablative conditioning, where strong chemotherapy is used to clear out your bone marrow to make room for the new, edited cells [18][20]. Because this process is intense and requires highly specialized care, these therapies can only be administered at specific hospitals known as Qualified Treatment Centers (QTCs) [18][21].

For the patient, this means:

  • Relocation Costs: You may need to relocate to a city with a QTC for several months, resulting in substantial travel and lodging expenses [18][19].
  • Caregiver Expenses: You will need a full-time caregiver during your recovery, which often leads to lost income for both you and your support system [18][19][22].
  • Insurance Copays: Even if the $2.8 million drug is covered, you will still likely be responsible for hitting your insurance policy’s out-of-pocket maximum for the year.

To help navigate these indirect barriers, manufacturers often offer Patient Assistance Programs (PAPs). These programs provide specialized financial navigators who can help you appeal insurance denials and may offer financial assistance to offset travel, lodging, and out-of-pocket costs during your treatment.

One-Time Cost vs. Lifetime Care

When reviewing a $2.8 million price tag, it is essential to understand why health economists and insurers consider these gene therapies “cost-effective” [23][24][25].

The standard of care for transfusion-dependent beta-thalassemia (TDT) requires lifelong regular red blood cell transfusions and daily iron chelation therapy [26][27][28]. This imposes a massive, ongoing economic burden on the healthcare system and families [29][30]. The costs pile up from:

  • Frequent hospital visits and the administration of blood transfusions [29][31][32].
  • The high cost of daily iron chelation medications [29][31].
  • Managing chronic complications from iron overload (excess iron buildup in the organs), which can lead to cardiac failure, liver fibrosis, and endocrine disorders that require intensive medical interventions [33][34][35].

While one baseline global study estimated the direct lifetime healthcare cost for a TDT patient receiving standard care to be roughly $606,665 [36], the true economic burden in the United States is often estimated to be several times higher. Medical complications and healthcare resource utilization escalate significantly as patients age into adulthood [37][38], and families face massive indirect costs from decades of lost productivity [30][29].

By potentially eliminating the need for regular transfusions and halting the damage from iron overload, a successful one-time gene therapy offsets decades of continuous healthcare expenses and drastically improves a patient’s long-term survival and quality of life [23][39][40].

Common questions in this guide

How much do Zynteglo and Casgevy cost?
Zynteglo is priced at approximately $2.8 million, and Casgevy costs around $2.2 million per patient. These high prices reflect the complex research, sophisticated manufacturing required to edit a patient's own cells, and the nature of creating a one-time transformative treatment.
How does insurance cover the cost of gene therapy?
Many insurers and Medicaid programs use value-based agreements, meaning payment is directly linked to how well the therapy works. If the treatment successfully frees a patient from needing blood transfusions for at least 12 months, the therapy is paid for; if not, the manufacturer may provide a refund.
What are the eligibility requirements for insurance to approve Zynteglo or Casgevy?
Insurers usually require precise genetic confirmation of your beta-thalassemia severity. They also frequently require proof that you do not have an HLA-matched sibling donor, which means you do not have a brother or sister who could safely provide a traditional stem cell transplant.
Are there hidden costs for patients getting gene therapy?
Yes. Beyond the drug price, receiving gene therapy requires intense preparation and specialized care at specific hospitals. Patients often face substantial hidden costs for relocating to a treatment center for several months, paying for lodging, funding a full-time caregiver, and hitting their insurance's annual out-of-pocket maximum.
Why is a multi-million dollar gene therapy considered cost-effective?
While the initial price is in the millions, standard care for transfusion-dependent beta-thalassemia involves lifelong blood transfusions and daily medications, which cost hundreds of thousands of dollars over a lifetime. A successful one-time gene therapy offsets decades of continuous healthcare expenses and prevents costly medical complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my specific beta-thalassemia genotype and clinical history make me eligible for Zynteglo or Casgevy under most insurance policies?
  2. 2.Have I been formally tested to confirm whether I have an HLA-matched sibling donor, and is that documentation ready for my prior authorization?
  3. 3.Does your treatment center work with my insurance's specific value-based agreements for gene therapies?
  4. 4.What is the typical timeline for an insurance prior authorization for gene therapy at your clinic, from initial submission to final approval?
  5. 5.Can you connect me with a social worker or financial navigator to help me understand my out-of-pocket maximums and identify patient assistance programs for travel and lodging?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

New Meds to Reduce Beta-Thalassemia Transfusions?Does Beta-Thalassemia Major Affect Growth & Puberty?Does Beta-Thalassemia Gene Therapy Cause Infertility?Why Does Beta-Thalassemia Cause Bone & Facial Changes?How Do Zynteglo & Casgevy Work for Beta-Thalassemia?How to Manage Teen Beta-Thalassemia Treatment BurnoutChances of Beta-Thalassemia Major for Carrier ParentsWhat Happens If You Miss Iron Chelation Doses?What Is a Cardiac T2* MRI for Thalassemia?What Is the Life Expectancy for Beta-Thalassemia Major?What is the Pesaro Score for Stem Cell Transplants?Why Do You Need Vision & Hearing Exams With Chelation?Why Do Beta-Thalassemia Symptoms Start at 3-6 Months?Why is Spleen Removal Needed for Beta-Thalassemia?

References

References (40)
  1. 1

    Gene Therapy: A Revolutionary Step in Treating Thalassemia.

    Malay J, Salama RAA, Alam Qureshi GS, et al.

    Hematology reports 2024; (16(4)):656-668 doi:10.3390/hematolrep16040064.

    PMID: 39449307
  2. 2

    Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model.

    Zemplenyi A, Leonard J, Wright GC, et al.

    PharmacoEconomics 2025; (43(5)):583-594 doi:10.1007/s40273-025-01474-3.

    PMID: 39982606
  3. 3

    A roadmap for affordable genetic medicines.

    Kliegman M, Zaghlula M, Abrahamson S, et al.

    Nature 2024; (634(8033)):307-314 doi:10.1038/s41586-024-07800-7.

    PMID: 39019069
  4. 4

    Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.

    Segura EER, Ayoub PG, Hart KL, Kohn DB

    Viruses 2023; (15(3)) doi:10.3390/v15030713.

    PMID: 36992422
  5. 5

    Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

    Bangolo A, Amoozgar B, Zhang L, et al.

    Biomedicines 2025; (13(8)) doi:10.3390/biomedicines13082022.

    PMID: 40868273
  6. 6

    Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.

    Ng QX, Ong C, Chan KE, et al.

    Health economics review 2024; (14(1)):42 doi:10.1186/s13561-024-00519-1.

    PMID: 38896399
  7. 7

    Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.

    Zemplenyi A, Leonard J, DiStefano MJ, et al.

    PharmacoEconomics 2024; (42(3)):319-328 doi:10.1007/s40273-023-01335-x.

    PMID: 37989969
  8. 8

    Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.

    Jørgensen J, Hanna E, Kefalas P

    Journal of market access & health policy 2020; (8(1)):1715536 doi:10.1080/20016689.2020.1715536.

    PMID: 32082514
  9. 9

    Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

    Koleva-Kolarova R, Buchanan J, Vellekoop H, et al.

    Applied health economics and health policy 2022; (20(4)):501-524 doi:10.1007/s40258-021-00714-9.

    PMID: 35368231
  10. 10

    Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.

    Kwiatkowski JL, Walters MC, Hongeng S, et al.

    Lancet (London, England) 2024; (404(10468)):2175-2186 doi:10.1016/S0140-6736(24)01884-1.

    PMID: 39527960
  11. 11

    Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.

    Locatelli F, Thompson AA, Kwiatkowski JL, et al.

    The New England journal of medicine 2022; (386(5)):415-427 doi:10.1056/NEJMoa2113206.

    PMID: 34891223
  12. 12

    The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

    Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R

    PharmacoEconomics 2019; (37(12)):1469-1483 doi:10.1007/s40273-019-00838-w.

    PMID: 31535280
  13. 13

    Acuerdos de Riesgo Compartido: Lecciones Para su Diseño e Implementación a la Luz de la Experiencia Internacional.

    María Paredes Fernández D, Christian Lenz Alcayaga R

    Value in health regional issues 2019; (20()):51-59 doi:10.1016/j.vhri.2018.12.004.

    PMID: 30870806
  14. 14

    Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.

    Kaló Z, Niewada M, Bereczky T, et al.

    Expert review of pharmacoeconomics & outcomes research 2024; (24(2)):181-187 doi:10.1080/14737167.2023.2282680.

    PMID: 37970637
  15. 15

    Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars.

    Otte M, Kaló Z, Al-Omar HA, et al.

    Frontiers in pharmacology 2025; (16()):1599013 doi:10.3389/fphar.2025.1599013.

    PMID: 40880644
  16. 16

    Successful treatment of transfusion-dependent β-thalassemia: multiple paths to reach potential cure.

    Morgan M, Schambach A

    Signal transduction and targeted therapy 2025; (10(1)):55 doi:10.1038/s41392-025-02135-9.

    PMID: 39956809
  17. 17

    Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.

    Hongeng S, Anurathapan U, Songdej D, et al.

    Blood advances 2021; (5(13)):2701-2706 doi:10.1182/bloodadvances.2020003680.

    PMID: 34196676
  18. 18

    Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access Challenges.

    Butt H, Mandava M, Jacobsohn D

    The CRISPR journal 2025; (8(3)):174-188 doi:10.1089/crispr.2024.0101.

    PMID: 40356202
  19. 19

    Unlocking patient access to gene therapy: five key practices.

    Salimullah T, Kazazoglu Taylor B, Zerbato M

    Gene therapy 2025; (32(2)):75-77 doi:10.1038/s41434-024-00509-2.

    PMID: 39643708
  20. 20

    Hematopoietic stem cell collection for sickle cell disease gene therapy.

    Leonard A, Weiss MJ

    Current opinion in hematology 2024; (31(3)):104-114 doi:10.1097/MOH.0000000000000807.

    PMID: 38359264
  21. 21

    Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

    Inam Z, Han H, Webb J, Delaney M

    Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.

    PMID: 41223813
  22. 22

    Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.

    Testa U, Castelli G, Pelosi E

    Journal of clinical medicine 2026; (15(4)) doi:10.3390/jcm15041379.

    PMID: 41753067
  23. 23

    Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

    Kansal AR, Reifsnider OS, Brand SB, et al.

    Journal of market access & health policy 2021; (9(1)):1922028 doi:10.1080/20016689.2021.1922028.

    PMID: 34178295
  24. 24

    Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.

    Porter J

    Hematology. American Society of Hematology. Education Program 2018; (2018(1)):361-370 doi:10.1182/asheducation-2018.1.361.

    PMID: 30504333
  25. 25

    Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.

    John MJ, Jyani G, Jindal A, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(10)):2119-2126 doi:10.1016/j.bbmt.2018.04.005.

    PMID: 29673692
  26. 26

    Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients.

    Russo V, Rago A, Papa AA, Nigro G

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2016; (21(4)):335-42 doi:10.1111/anec.12389.

    PMID: 27324981
  27. 27

    Increasing prevalence of thalassemia in America: Implications for primary care.

    Sayani FA, Kwiatkowski JL

    Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.

    PMID: 26541064
  28. 28

    β-Thalassemia.

    Origa R

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(6)):609-619 doi:10.1038/gim.2016.173.

    PMID: 27811859
  29. 29

    Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

    Alshamsi S, Hamidi S, Narci HO

    BMC health services research 2022; (22(1)):304 doi:10.1186/s12913-022-07663-6.

    PMID: 35248046
  30. 30

    Productivity Loss and Associated Costs Among Patients with Transfusion-Dependent Thalassemia in Dubai, United Arab Emirates.

    Alshamsi S, Hamidi S, Ozgen Narci H

    ClinicoEconomics and outcomes research : CEOR 2021; (13()):853-862 doi:10.2147/CEOR.S334724.

    PMID: 34616164
  31. 31

    Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India.

    Dhanya R, Sedai A, Ankita K, et al.

    Blood advances 2020; (4(7)):1448-1457 doi:10.1182/bloodadvances.2019000760.

    PMID: 32282881
  32. 32

    Quality of Life and Related Paraclinical Factors in Iranian Patients with Transfusion-Dependent Thalassemia.

    Khodashenas M, Mardi P, Taherzadeh-Ghahfarokhi N, et al.

    Journal of environmental and public health 2021; (2021()):2849163 doi:10.1155/2021/2849163.

    PMID: 34457009
  33. 33

    Survival and causes of death in patients with alpha and beta-thalassemia in Northern Thailand.

    Tantiworawit A, Kamolsripat T, Piriyakhuntorn P, et al.

    Annals of medicine 2024; (56(1)):2338246 doi:10.1080/07853890.2024.2338246.

    PMID: 38604224
  34. 34

    Impact of iron chelation therapy on thyroid function in beta-thalassemia major patients from Pakistan.

    Shah AWA, Shams S, Khan MJ, et al.

    Scientific reports 2026; (16(1)).

    PMID: 41644586
  35. 35

    Spectrum of Adrenal Dysfunction in Hemoglobin E/Beta Thalassemia.

    Singha A, Mukhopadhyay P, Ghosh S

    The Journal of clinical endocrinology and metabolism 2024; (109(2)):e562-e568 doi:10.1210/clinem/dgad579.

    PMID: 37772731
  36. 36

    Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.

    Shafie AA, Wong JHY, Ibrahim HM, et al.

    Orphanet journal of rare diseases 2021; (16(1)):157 doi:10.1186/s13023-021-01791-8.

    PMID: 33827621
  37. 37

    Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β-Thalassemia in England.

    Udeze C, Ly NF, Ingleby FC, et al.

    Clinical therapeutics 2025; (47(1)):37-43 doi:10.1016/j.clinthera.2024.09.024.

    PMID: 39488494
  38. 38

    Epidemiological and comorbidity burden in transfusion-dependent patients with thalassemia and sickle cell disease in Greece.

    Delicou S, Xydaki A, Kamposou V, et al.

    Annals of hematology 2026; (105(3)):95.

    PMID: 41649569
  39. 39

    Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.

    Hamed EM, Meabed MH, Aly UF, Hussein RRS

    Current drug targets 2019; (20(16)):1603-1623 doi:10.2174/1389450120666190726155733.

    PMID: 31362654
  40. 40

    An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia.

    Handgretinger R, Mezger M

    Expert opinion on biological therapy 2024; (24(9)):883-888 doi:10.1080/14712598.2024.2399134.

    PMID: 39222044

This page provides educational information regarding the cost of gene therapies and is for informational purposes only. It does not replace professional medical or financial advice. Always consult your healthcare provider and an insurance or financial navigator regarding your specific coverage.

Get notified when new evidence is published on Beta-thalassemia major.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.